Mass Tort brief
UK High Court Reshapes Emissions Suits as US Courts Reopen Pharma Exposure
A landmark Dieselgate ruling and SRA litigation funding rules reshape UK class actions while US courts revive marketing and injury claims against Haleon, GSK, and Pfizer.
Mass Tort
The High Court dismissed Pan-NOx claims against major automakers — delivering a severe setback to litigation funders backing UK emissions group actions.
BackgroundThe Pan-NOx group litigation order represents the largest consumer class action in English legal history, targeting multiple car manufacturers over alleged emissions defeat devices. Commercial litigation funders invested hundreds of millions of pounds funding claimant group legal representation.
- Mrs Justice Cockerill adopted a narrow definition of prohibited defeat devices, dismissing all allegations against Ford, Renault, and Nissan.
- The ruling established that vehicle purchasers possess a private right of action in damages under UK emissions regulations, creating clear precedent for future UK consumer group actions.
- Substantive findings against litigation-backed claims significantly increase financial risk for litigation funders backing future UK group action suits.
Mass Tort
US appellate court ruled the PREP Act immunizes AstraZeneca from trial injury claims — removing product liability exposure for the UK drugmaker.
BackgroundThe Public Readiness and Emergency Preparedness (PREP) Act grants broad statutory immunity to pharmaceutical manufacturers developing pandemic countermeasures. Claimants sought to bypass statutory immunity by alleging breach of contract during COVID-19 clinical trials.
- The appellate court ruled statutory PREP Act immunity covers breach-of-contract claims stemming from pandemic vaccine trials, blocking backdoor plaintiff strategies.
- Remanded the case to lower courts solely to determine whether AstraZeneca implicitly waived immunity during trial contracting, leaving only a narrow legal avenue.
- Protects London-listed AstraZeneca from expanding product liability exposure across US federal courts, reassuring pharmaceutical investors.
Mass Tort
A US appeals court revived false-advertising claims against Haleon and GSK — exposing FTSE consumer health brands to decongestant marketing litigation.
BackgroundOral phenylephrine decongestants faced mass litigation after FDA advisory panels questioned the ingredient's effectiveness. While general efficacy claims were preempted by federal rules, marketing descriptions like 'maximum strength' remain subject to state consumer protection laws.
- The 2nd Circuit panel ruled that manufacturers voluntarily using 'maximum strength' labels face state false-advertising claims, reversing a lower court dismissal.
- Refreshes legal liabilities for London-listed Haleon, maker of Advil Sinus Congestion, and pharmaceutical firm GSK across consolidated federal dockets.
- Reverses a prior district court dismissal, sending multidistrict litigation back to federal court for discovery proceedings that could force financial settlements.
Mass Tort
J&J proposed a $5.5B talc settlement to resolve 70,000 lawsuits — seeking a 95% opt-in to cap liabilities across US courts.
BackgroundJohnson & Johnson faced tens of thousands of personal injury lawsuits across US federal and state courts claiming asbestos contamination in talcum powder. UK-listed spinoff Kenvue holds indemnification agreements that connect European investors to US talc settlement resolutions.
- Requires 95% claimant approval, with initial payout installments capped at $3 billion starting in 2027 to limit immediate cash burn.
- Follows a favorable federal MDL evidentiary ruling requiring plaintiffs to prove specific scientific causation, strengthening defense negotiating leverage.
- Legal analysts note UK litigation and non-participating claimants remain unaddressed, preserving lingering investor exposure for spin-off Kenvue.
Mass Tort
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.